NXTCHIGH SIGNALFINANCIAL10-K

NXTC shows severe financial deterioration with stockholders equity collapsing 46.6% and total assets declining 38% despite revenue growth of 253%.

The dramatic decline in stockholders equity and total assets, combined with worsening operating cash flow losses, suggests the company is burning through capital at an unsustainable rate. The massive share count reduction from 28M to 3.6M shares indicates either a significant reverse stock split or major dilutive financing that has severely impacted shareholder value.

Comparing 2026-03-05 vs 2025-03-06View on EDGAR →
FINANCIAL ANALYSIS

While revenue surged 253% to $22.4M, this growth was overshadowed by massive balance sheet deterioration with stockholders equity falling 47% to $34.9M and total assets declining 38% to $50.2M. Operating cash flow losses worsened 22% to -$49.6M while current assets dropped 39%, indicating the company is rapidly consuming capital despite revenue improvements. The overall financial picture signals a company in severe distress, burning cash faster than it can generate revenue growth, with shareholder value being decimated through what appears to be emergency financing or restructuring activities.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+252.6%
$6.3M$22.4M

Strong top-line growth of 252.6% — accelerating demand or successful expansion into new markets.

Stockholders Equity
Balance Sheet
-46.6%
$65.5M$34.9M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Capital Expenditure
Cash Flow
-42.2%
$820K$474K

Capex reduced 42.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Assets
Balance Sheet
-39.1%
$71.8M$43.7M

Current assets declined 39.1% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-37.9%
$80.9M$50.2M

Total assets contracted 37.9% — asset sales, write-downs, or balance sheet optimization underway.

Operating Cash Flow
Cash Flow
-21.6%
-$40.8M-$49.6M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Current Liabilities
Balance Sheet
+10.4%
$9.6M$10.6M

Current liabilities rose 10.4% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-03-05
PRIOR — 2025-03-06
ADDED
As of February 27, 2026, the registrant had 3,560,410 shares of common stock, par value $0.001 per share, issued and outstanding.
or hereinafter LigaChem ), Simcere Zaiming Pharmaceutical Co, Ltd.
(formerly known as Hainan Simcere Zaiming Pharmaceutical, Ltd.
or hereinafter Zaiming ), and other third-party vendors and collaborators; our ability to retain key personnel; our intended reliance on and the performance of third parties, including collaborators, contract research organizations and third-party manufacturers; changes in international relations, tariffs, and other trade regulations between the U.S.
and China; our ability to protect and enforce our intellectual property protection and the scope and duration of such protection; developments and projections relating to our competitors and our industry, including competing therapies; and the impact of current and future laws and regulations.
+7 more — sign up free →
REMOVED
As of March 3, 2025, the registrant had 28,006,684 shares of common stock, par value $0.001 per share, issued and outstanding.
We may be unable to secure sufficient quantities of our product candidates economically, or at the necessary scale, whether through use of a third party, by scaling up our paused manufacturing operations, or by otherwise failing to source adequate supply of our product candidates which would delay or prevent us from developing and, if approved, commercializing our product candidates.
We are currently not in compliance with the continued listing standards of the Nasdaq Global Select Market, and if we are unable to regain compliance, our common stock will be delisted from the exchange.
Since inception, we have devoted substantially all of our efforts and financial resources to discovery, research and development activities for our product candidates, identifying business development opportunities, raising capital and securing intellectual property rights related to our product candidates.
B7-H4, a clinically validated target, is a cell surface protein expressed on multiple tumor types including breast, ovarian and endometrial cancers, that we believe represents a large market opportunity.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →